Disc Medicine (NASDAQ:IRON) Stock Rating Reaffirmed by HC Wainwright

Disc Medicine (NASDAQ:IRONGet Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $70.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 118.51% from the stock’s current price.

A number of other analysts have also recently commented on IRON. Cantor Fitzgerald restated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research note on Wednesday, December 20th. BMO Capital Markets upped their price target on shares of Disc Medicine from $70.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. Morgan Stanley cut shares of Disc Medicine from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $56.00 to $65.00 in a research note on Tuesday, December 19th. Finally, Wedbush reiterated an “outperform” rating and issued a $84.00 target price (up from $79.00) on shares of Disc Medicine in a research note on Thursday, March 21st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Disc Medicine has a consensus rating of “Moderate Buy” and an average price target of $57.00.

Read Our Latest Report on IRON

Disc Medicine Trading Down 6.4 %

Shares of IRON stock opened at $32.04 on Monday. The stock has a market capitalization of $773.32 million, a P/E ratio of -9.18 and a beta of 0.18. The firm’s 50 day moving average is $64.16 and its 200 day moving average is $57.00. Disc Medicine has a 12 month low of $20.05 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRONGet Free Report) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.22). On average, equities analysts predict that Disc Medicine will post -4.37 EPS for the current year.

Insider Activity

In other news, Director Kevin Bitterman sold 102,500 shares of the firm’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $67.65, for a total transaction of $6,934,125.00. Following the sale, the director now owns 198,326 shares in the company, valued at approximately $13,416,753.90. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Kevin Bitterman sold 102,500 shares of the stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $67.65, for a total transaction of $6,934,125.00. Following the transaction, the director now owns 198,326 shares of the company’s stock, valued at approximately $13,416,753.90. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Venture Fund X. L.P. Atlas sold 30,000 shares of the stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $64.00, for a total transaction of $1,920,000.00. Following the transaction, the insider now directly owns 1,449,686 shares in the company, valued at approximately $92,779,904. The disclosure for this sale can be found here. In the last quarter, insiders have sold 200,000 shares of company stock worth $13,347,500. 4.71% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Disc Medicine

Large investors have recently added to or reduced their stakes in the company. Strs Ohio bought a new stake in Disc Medicine in the 3rd quarter worth $28,000. Ameritas Investment Partners Inc. bought a new stake in Disc Medicine in the 2nd quarter worth $28,000. Steward Partners Investment Advisory LLC grew its holdings in Disc Medicine by 50.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 600 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the last quarter. Bank of America Corp DE grew its holdings in Disc Medicine by 134,000.0% in the 1st quarter. Bank of America Corp DE now owns 2,682 shares of the company’s stock worth $57,000 after acquiring an additional 2,680 shares during the last quarter. Finally, AJOVista LLC bought a new stake in Disc Medicine in the 4th quarter worth $63,000. Institutional investors own 83.70% of the company’s stock.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc, together with its subsidiaries, operates as a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Featured Stories

Analyst Recommendations for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.